Claims for Patent: 10,364,466

Summary for Patent: 10,364,466

Title:	Biological markers for identifying patients for treatment with VEGF antagonists
Abstract:	The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods.
Inventor(s):	Bais; Carlos (San Francisco, CA), Brauer; Matthew (San Francisco, CA), Singh; Mallika (San Francisco, CA), Schmidt; Maike (San Francisco, CA)
Assignee:	Genentech, Inc. (South San Francisco, CA)
Application Number:	13/836,535
Patent Claims:	1. A method of optimizing therapeutic efficacy of a VEGF antagonist for a patient, the method comprising: (a) detecting expression of at least three genes set forth in Table 2 in a sample obtained from the patient prior to any administration of a VEGF antagonist to the patient; (b) comparing the expression level of the at least three genes to a reference expression level of the at least three genes, wherein a change in the level of expression of the at least three genes in the patient sample relative to the reference expression level identifies a patient who is likely to respond to treatment with a VEGF antagonist; and (c) administering a VEGF antagonist to the patient identified in step (b) as likely to respond to treatment with a VEGF antagonist, wherein the VEGF antagonist is an anti-VEGF antibody and the change in the level of expression of the at least three genes in the patient sample is an increase relative to the reference expression level. 2. A method for treating an angiogenic disorder in a patient, the method comprising: (a) determining that a sample obtained from the patient has a level of at least three genes set forth in Table 2 that is above a reference expression level of the at least three genes; and (b) administering an effective amount of a VEGF antagonist, wherein the VEGF antagonist is an anti-VEGF antibody. 3. A method of treating a patient identified as likely to respond to treatment with a VEGF antagonist, the method comprising: (a) detecting expression of at least three genes set forth in Table 2 in a sample obtained from the patient prior to any administration of a VEGF antagonist to the patient; (b) comparing the expression level of the at least three genes to a reference expression level of the at least three genes, wherein a change in the level of expression of the at least three genes in the patient sample relative to the reference expression level identifies a patient who is likely to respond to treatment with a VEGF antagonist; and (c) administering a VEGF antagonist to the patient identified in step (b) as likely to respond to treatment with a VEGF antagonist, wherein the VEGF antagonist is an anti-VEGF antibody and the change in the level of expression of the at least three genes in the patient sample is an increase relative to the reference expression level. 4. The method of any one of claims 3, 1, and 2, wherein the anti-VEGF antibody is bevacizumab. 5. The method of claim 3 or 1, wherein the patient has an angiogenic disorder. 6. The method of claim 5, wherein the angiogenic disorder is a cancer selected from the group consisting of: colorectal cancer, breast cancer, lung cancer, glioblastoma, and combinations thereof. 7. The method of claim 3, wherein the patient is in a population of patients being tested for responsiveness to a VEGF antagonist and the reference expression level is the median level of expression of the at least three genes in the population of patients. 8. The method of claim 3, wherein expression of the at least three genes in the sample obtained from the patient is detected by measuring mRNA. 9. The method of claim 3, wherein expression of the at least three genes in the sample obtained from the patient is detected by measuring plasma protein levels. 10. The method of claim 3, wherein the sample is tumor tissue. 11. The method of claim 3, further comprising detecting expression of at least a fourth gene set forth in Table 2 in the sample from the patient. 12. The method of claim 3, wherein the change in the level of expression of the at least three genes in the patient sample relative to the reference expression level is determined by calculating a VDV signature score (VDV.sub.i) for the patient sample according to the algorithm: .times..times..times. ##EQU00004## wherein Z.sub.g=1,i, Z.sub.g=2,i, . . . Z.sub.g=n,i are standardized z-scores of expression values for each gene g, from g=1 to g=n, of the sample i, and wherein a VDV.sub.i below a first defined threshold indicates a decrease relative to the reference expression level, and a VDV.sub.i above a second defined threshold indicates an increase relative to the reference expression level. 13. The method of claim 12, wherein the expression values for each gene g, from g=1 to g=n, are qRT-PCR values for each gene g, from g=1 to g=n. 14. The method of claim 12, wherein the first defined threshold is from -4 to -0.5 and the second defined threshold is from 0.5 to 4. 15. The method of claim 14, wherein the first defined threshold is from -4 to -1 and the second defined threshold is from 1 to 4. 16. The method of claim 15, wherein the first defined threshold is from -4 to -1.5 and the second defined threshold is from 1.5 to 4. 17. The method of claim 16, wherein the first defined threshold is from -4 to -2 and the second defined threshold is from 2 to 4.

Details for Patent 10,364,466

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2032-01-13